Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: DreamCIS, Inc.

Market Cap 82.53B 53.67M 46.89M 43.38M 40.49M 76M 5.07B 76.56M 515M 201M 2.49B 201M 197M 8.66B P/E 2026 *
8.87x
P/E 2027 * 6.59x
Enterprise Value 39.53M 25.71K 22.46K 20.78K 19.39K 36.41K 2.43M 36.67K 247K 96.07K 1.19M 96.51K 94.42K 4.15M EV / Sales 2026 *
0.44x
EV / Sales 2027 * 0.27x
Free-Float
30.64%
Yield 2026 *
-
Yield 2027 * -
03-22 DreamCIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
12-01 Curi Bio, Inc. announced that it has received $10 million in funding from DreamCIS, Inc. CI
11-10 DreamCIS, Inc. agreed to acquire 13.01% stake in Curi Bio, Inc. CI
11-10 Curi Bio, Inc. announced that it expects to receive $14.848537 million in funding from DreamCIS, Inc. CI
25-09-29 DreamCIS, Inc. announced that it has received KRW 15 billion in funding from Hong Kong Tigermed Co., Ltd., NH Investment & Securities Co., Ltd., KB Securities Co., Ltd., Korea Investment & Securities Co., Ltd. CI
25-09-21 DreamCIS, Inc. announced that it expects to receive KRW 15 billion in funding from Hong Kong Tigermed Co., Ltd., NH Investment & Securities Co., Ltd., KB Securities Co., Ltd., Korea Investment & Securities Co., Ltd. and other investors CI
24-02-22 Curi Bio, Genetox and DreamCIS Sign MOU for Strategic Collaboration on 3D Neuromuscular Junction Model for Botox Potency Assay CI
23-12-21 T&R Biofab Co., Ltd. announced that it has received KRW 1.999996 billion in funding from Korea Investment Partners Co. Ltd., DreamCIS, Inc. CI
23-12-13 T&R Biofab Co., Ltd. announced that it expects to receive KRW 1.999996 billion in funding from Korea Investment Partners Co. Ltd., DreamCIS, Inc. CI
23-03-21 DreamCIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
22-03-27 DreamCIS, Inc. announced that it has received KRW 2.9999925 billion in funding CI
22-03-16 DreamCIS, Inc. announced that it expects to receive KRW 2.9999925 billion in funding CI
20-05-21 DreamCIS, Inc. has completed an IPO in the amount of KRW 20.186311 billion. CI
1 day-0.56%
1 week-7.09%
Current month-28.48%
1 month-38.43%
3 months-31.40%
6 months-53.97%
Current year-44.51%
1 week 3,460
Extreme 3460
4,185
1 month 3,460
Extreme 3460
6,670
Current year 3,460
Extreme 3460
8,640
1 year 3,095
Extreme 3095
8,640
3 years 2,435
Extreme 2435
9,750
5 years 2,370
Extreme 2370
9,750
10 years 2,370
Extreme 2370
9,750
Manager TitleAgeSince
Chief Executive Officer 56 2022-03-29
Director of Finance/CFO 57 2016-04-30
Director TitleAgeSince
Director/Board Member 45 2019-08-29
Director/Board Member 57 2016-04-30
Director/Board Member 53 2019-08-29
Date Insider Type Main position Quantity % Market Cap.
24-12-15Buy

Chief Executive Officer

30,000 0.1261%
Change 5-day change 1-year change 3-year change Capi.($)
-0.56%-7.09%-8.53%+9.34% 56.62M
+2.26%+5.05%+35.72%+350.11% 32.77B
+1.72%-2.81%-1.43%+9.58% 20.86B
+0.10%+0.86%-23.58%-42.92% 6.86B
+1.43%+0.18%+3.17%+69.29% 4.38B
-0.13%+1.68%+19.09%+58.27% 2.96B
+5.22%-6.44%-28.87%+824.96% 1.65B
+0.12%-0.65%-8.65%-66.59% 1.68B
+7.62%+4.03%+44.44%-24.96% 1.77B
-1.25%+1.42%+13.20%-6.94% 1.59B
Average +1.64%-1.42%+4.46%+118.01% 7.46B
Weighted average by Cap. +1.80%+1.08%+14.57%+174.91%

Financials

2026 *2027 *
Net sales 90B 58.52M 51.13M 47.3M 44.15M 82.88M 5.53B 83.48M 562M 219M 2.72B 220M 215M 9.45B 117B 75.98M 66.39M 61.41M 57.32M 108M 7.18B 108M 730M 284M 3.53B 285M 279M 12.26B
Net income 9.8B 6.37M 5.57M 5.15M 4.81M 9.02M 602M 9.09M 61.2M 23.81M 296M 23.92M 23.41M 1.03B 13.2B 8.58M 7.5M 6.94M 6.47M 12.16M 811M 12.24M 82.44M 32.08M 399M 32.22M 31.53M 1.39B
Net Debt -43B -27.96M -24.43M -22.6M -21.09M -39.6M -2.64B -39.89M -269M -104M -1.3B -105M -103M -4.51B -51B -33.16M -28.98M -26.8M -25.02M -46.96M -3.13B -47.31M -319M -124M -1.54B -125M -122M -5.35B
Logo DreamCIS, Inc.
DreamCIS Inc is a Korea-based company principally engaged in the business of contract clinical trial. The Company mainly provides services include regulatory post-marketing surveillance (rPMS), clinical trial, non-interventional study (NIS) and others. The Company provides its services within domestic market and to overseas markets.
Employees
391
Date Price Change Volume
26-06-22 ₩3,540.00 -0.56% 88,358
26-06-19 ₩3,560.00 -4.56% 157,517
26-06-18 ₩3,730.00 -5.45% 135,792
26-06-17 ₩3,945.00 +0.38% 183,880
26-06-16 ₩3,930.00 +3.15% 85,578
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A223250 Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!